Industry Urges FDA to Reduce Scrutiny of Low-Risk Importers
This article was originally published in The Gold Sheet
Executive Summary
The pharmaceutical industry generally supports the idea of FDA proposing a certified importer program for highly compliant manufacturers but urges caution in how risk levels for different importers would be assigned under FDA’s pending import regulations. They also say that low-risk importers should be subject to less scrutiny than high-risk ones.